Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  CELLCEUTIX    CTIX

SummaryNewsCompany 
News SummaryMost relevantAll newsSector news 

Cellceutix Corp : Small Cap Stocks in Focus Today are CTIX, CWGL, FNRC and DEWM

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/29/2013 | 05:50am CET

Cellceutix (OTC: CTIX),The Crimson Wine Group (OTC: CWGL), 1st NRG Corp. (PINK: FNRC) and Dewmar International BMC, Inc. (OTC: DEWM) are our Small Cap Stocks in focus today.

Cellceutix (OTC: CTIX) is a clinical stage biopharmaceutical company developing and commercializing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world class portfolio of compounds and is now engaged in advancing its existing portfolio of clinical compounds and strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. Kevetrin in the laboratory has been shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations.

For our complete article on CTIX please go here: http://tinyurl.com/otcmagic-cellceutix

The Crimson Wine Group (OTC: CWGL) owns and operates boutique, estate-based wineries that produce world class wines in the finest wine growing regions of California, Oregon and Washington. With a commitment to the preeminent appellations and vineyard sites of each region, a philosophy of hand-crafted quality and with the highest respect for the land, each CWG property produces distinct varietal wines that reflect the finest characteristics of their place of origin.

For our complete article on CWGL please go here: http://tinyurl.com/otcmagic-crimson

1st NRG Corp. (PINK: FNRC) is an exploration and production company headquartered in Denver, Colorado whose activity to date has been centered on development of the Clabaugh Ranch Field, a project developing and producing coal bed methane reserves (CBM) located in the Powder River Basin of Wyoming.

On October 21 FNRC announced a New Drilling and Production Revenues for CBM Properties in Wyoming

For our complete article on FNRC please go here: http://tinyurl.com/otcmagic-fnrc

Dewmar International BMC, Inc. (OTC: DEWM) is a U.S. based new product development, manufacturing and brand management company. Established in 2003, Dewmar's primary business strategy has been in creating high profit margins with functional foods and beverages. The Company's flagship product, Lean Slow Motion Potion, whose flavors include Yella, Purp and Easta Pink, is rated as one of the top 3 national selling relaxation beverages in the U.S. market. The company has offices in Clinton, MS; Las Vegas, NV and Houston, TX.

For our complete article on DEWM please go here: http://tinyurl.com/otcmagic-dewm

OTCMAGIC is a newsletter that reports on developments in the world of penny stocks. OTCMagic is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit OTCMagic.com website, for complete risks and disclosures.

Subscribe Here: http://www.otcmagic.com/

Contact Info:

OTCMagic
info@otcmagic.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELLCEUTIX
11/15 CELLCEUTIX CORP : Results of Operations and Financial Condition, Financial State..
11/14 Cellceutix Provides Corporate Update and Reports Q1 Fiscal 2017 Financial Res..
11/09 Cellceutix Announces Business Update Call at 10AM Eastern on November 15
11/09 CELLCEUTIX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RES..
11/01 CELLCEUTIX : Begins Phase 2b Clinical Trial of Oral Prurisol in Moderate-to-Seve..
10/31 Cellceutix Begins Phase 2b Clinical Trial of Oral Prurisol in Moderate-to-Sev..
10/26 Cellceutix Novel Anti-Inflammatory Phase 2 Drug Candidate Brilacidin Builds M..
10/21 CELLCEUTIX : University of Massachusetts Assigned Patent
10/10 Cellceutix Phase 2 Trial Initial Data Shows Potential of Brilacidin as a Nove..
09/16 CELLCEUTIX : Announces Appointment of Vice President for Regulatory Affairs
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
Advertisement
Managers
NameTitle
Leo Ehrlich Chairman, CEO, CFO, Secretary & CAO
Arthur Peter Bertolino President & Chief Medical Officer
Krishna Kumar Menon Director & Chief Science Officer
Daniel Jorgensen Chief Medical Officer
Barry Schechter Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELLCEUTIX0
AMGEN, INC.-11.29%107 132
GILEAD SCIENCES, INC.-28.02%95 410
CELGENE CORPORATION-1.78%91 187
REGENERON PHARMACEUTIC..-31.34%39 310
ACTELION LTD40.40%21 739
More Results